All in all, merging their favourable pre-clinical results with currently available clinical data provides a strong incentive to further explore catheter-based RDN as a therapeutic approach in CKD and other diseases related to sympathetic hyperactivity.
In their elegant study, Lopes and colleagues [6] described that chemical afferent renal denervation (ARD) decreased blood pressure (BP), renal sympathetic nerve activity (rSNA) and reactive oxygen species (ROS) in both kidneys and normalized renal function, proteinuria and activation of intrarenal renin-angiotensin system (RAS) in renovascular hypertensive animals. These data demonstrate that afferent renal nerves are crucial for the maintenance of BP and renal sympathetic hyperactivation, as well as renal function, in the renovascular hypertension model [6] .
Heightened sympathetic tone, a well-known risk factor for a range of cardiovascular diseases, is frequently present in patients with essential hypertension and those with chronic kidney disease (CKD) [2, 3] . In both hypertension and renal failure, the mechanisms contributing to the hyperadrenergic state are complex and include amongst other reflex and neurohumoral pathways [2, 3, 8] . Moreover, in CKD, sympathetic overactivity is already evident in the early stages and shows a direct relationship with the progression of renal impairment [11] .
BP control is principally achieved by the integrated renalendocrine systems that balance volume and sodium homeostasis. Renal sympathetic innervation consists of efferent sympathetic fibres arising from the central nervous system towards the kidneys, as well as afferent sensory fibres arising from the kidneys and projecting to the hypothalamus. Heightened sympathetic outflow to the renal vascular bed reduces renal blood flow, releases renin, thus activating the renin-angiotensin-aldosterone system (RAAS), triggering vasoconstriction and enhancing tubular reabsorption of urinary sodium and water (Fig. 1) . These mechanisms initiated by increased efferent SNS activity ultimately result in elevation of BP. The reduced renal blood flow stimulates the renal sensory nerves (afferent) with the consequence of increased central SNS outflow. Both central and local increase in SNS activity affect a large number of these pathways and have been associated with hypertension and its progression [4] .
Afferent renal nerve ablation leads to the mitigation of sympathetic signals arising from the kidneys to the brain, which per se lowers central sympathetic outflow ultimately reducing the efferent sympathetic nerve signalling to key organs. Beyond the already expected BP-lowering effect after renal afferent fibre disruption, Lopes and colleagues' findings provide us with a persuasive explanation about how a catheter-based renal denervation (RDN) approach may have caused the halt [9] or even improvement in renal function [5] that was noticed in patients with hypertension and CKD, as well as the reduction in albuminuria [5, 9] -an independent risk factor for cardiovascular events [7] and a predictor for the progression of CKD [1] . In view of the fact that albuminuria is an independent renal and cardiovascular risk factor, their data point out underpinning mechanisms through which RDN can mitigate the renal and cardiovascular risk in those patients. Fig. 1 Numerous types of renal injury can trigger increased afferent signalling, which is centrally integrated leading to increased sympathetic discharges to various organs, including the kidneys, and thereby stimulating renin secretion, Na + retention and vasoconstriction. The increased sympathetic output is also pointed towards other relevant organs (e.g. the heart and peripheral vessels), which can result in adverse outcomes. RAAS, reninangiotensin-aldosterone system; Na + , sodium; O 2 , oxygen. Adapted from [10] . Reproduced with permission
